Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04995562 · ClinicalTrials.gov registry record · Phase 4
Use of Hyperpolarized 129Xe MR Lung Imaging in Infants
A Phase 4 study of Lungs; Developmental Disorder, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04995562 is a Phase 4 study of Lungs; Developmental Disorder that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04995562, a Phase 4 study of Lungs; Developmental Disorder, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Abnormalities of the lungs are common in newborns and can include aspiration or infectious pneumonia, respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), pulmonary hypertension (PH), congenital diaphragmatic hernia (CDH), and other abnormalities of lung development. Diagnostic radiography is commonly used in this population to differentiate diagnosis and to assess changes after treatment. While X-ray and CT provide quality imaging, they also expose infants to ionizing radiation. MR imaging offers a safe, non-ionizing alternative. However, imaging lungs via 1H MR is intrinsically difficult due to multiple air-tissue interfaces within the lungs causing local gradients and severe magnetic field susceptibility, which leads to an exceedingly short effective transverse relaxation time (T2\*). Additionally, the lungs have low proton density, which along with the short T2\* results in low signal to noise ratio, and the physiological motion caused by respiration and cardiac pulsation further reduces lung signal. The development of more powerful hardware, along with faster MRI techniques, has enabled detailed noninvasive 1H MR imaging of pulmonary tissues. Additionally, the development of inhaled hyperpolarized gas MRI has led to breakthroughs in the ability to visualize and quantify regional ventilation and alveolar size.
Conditions Studied
Interventions
- DRUG 129Xe
Study Locations (1)
Ohio
- Megan Schmitt - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-05-06 |
| Est. Completion | 2028-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04995562
The ClinicalTrials.gov registry entry for NCT04995562 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lungs; Developmental Disorder appearing as the primary indexed condition, and to 1 intervention - of which 129Xe is the first listed.
NCT04995562 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04995562 about?
NCT04995562 is a clinical study titled "Use of Hyperpolarized 129Xe MR Lung Imaging in Infants". Abnormalities of the lungs are common in newborns and can include aspiration or infectious pneumonia, respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), pulmonary hypertension (PH), congenital diaphragmatic hernia (CDH), and other abnormalities of lung development. Diagnostic rad...
What is the current status of trial NCT04995562?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2020-05-06. Estimated completion is 2028-05-01.
What conditions does trial NCT04995562 study?
This clinical trial studies the following conditions: Lungs; Developmental Disorder.
What interventions are being tested in trial NCT04995562?
The interventions under investigation include: 129Xe (DRUG).
Who is sponsoring clinical trial NCT04995562?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04995562 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.